Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Chronic Hepatitis C virus (HCV) infection presents treatment challenges due to potential autoimmune phenomena.
• Interferon-alpha (IFNalpha) can exacerbate autoimmune symptoms, while corticosteroids may increase viral load.
• Intravenous immunoglobulins (IVIg) are explored for their immunomodulatory effects in HCV patients with autoimmunity.

Purpose of the Study:

• To evaluate the efficacy of combining IVIg with IFNalpha in treating chronic HCV patients with probable autoimmune disease.
• To compare the treatment outcomes of IFNalpha monotherapy versus combination therapy with IVIg and IFNalpha.

Main Methods:

• An open-label, randomized study involving 42 chronic HCV patients with positive autoimmune markers.
• Patients received either IVIg plus IFNalpha or IFNalpha alone for 6 months.
• Response was assessed by biochemical (alanine aminotransferase), virological (HCV clearance), immunological (Autoimmune Hepatitis score), and histological (HAI score) parameters.

Main Results:

• The combination group (IVIg + IFNalpha) showed a significantly higher percentage of complete virological and histological responses compared to IFNalpha alone (p = 0.04).
• Biochemical and immunological responses were also higher in the combination group, though not always statistically significant.
• IVIg may synergistically enhance the therapeutic effects of IFNalpha.

Conclusions:

• IVIg combined with IFNalpha demonstrates a positive prospective for treating chronic HCV patients with associated autoimmune disorders.
• The immunomodulating action of IVIg appears to enhance the response to IFNalpha treatment.
• This combination therapy may offer a more effective strategy for managing complex HCV cases involving autoimmunity.